Will DexCom Beat These Analyst Estimates?

Seth Jayson, The Motley Fool
Updated

DexCom (NAS: DXCM) is expected to report Q1 earnings on May 1. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict DexCom's revenues will expand 40.6% and EPS will remain in the red.

The average estimate for revenue is $28.3 million. On the bottom line, the average EPS estimate is -$0.17.


Revenue details
 Last quarter, DexCom logged revenue of $33.3 million. GAAP reported sales were 48% higher than the prior-year quarter's $22.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at -$0.15. GAAP EPS were -$0.12 for Q4 versus -$0.18 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 51.0%, 310 basis points better than the prior-year quarter. Operating margin was -27.9%, much better than the prior-year quarter. Net margin was -25.5%, much better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $129.4 million. The average EPS estimate is -$0.54.

Investor sentiment
 The stock has a one-star rating (out of five) at Motley Fool CAPS, with 79 members out of 176 rating the stock outperform, and 97 members rating it underperform. Among 61 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 23 give DexCom a green thumbs-up, and 38 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DexCom is outperform, with an average price target of $15.31.

Is DexCom the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

The article Will DexCom Beat These Analyst Estimates? originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement